Cargando…
Design, in silico and pharmacological evaluation of a peptide inhibitor of BACE-1
Introduction: Alzheimer’s disease (AD) is the main type of dementia, caused by the accumulation of amyloid plaques, formed by amyloid peptides after being processed from amyloid precursor protein (APP) by γ- and ß-secretases (BACE-1). Although amyloid peptides have been well established for AD, they...
Autores principales: | Boldin, Renata, Zychar, Bianca Cestari, Gonçalves, Luis Roberto C., Sciani, Juliana Mozer |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10313070/ https://www.ncbi.nlm.nih.gov/pubmed/37397495 http://dx.doi.org/10.3389/fphar.2023.1184006 |
Ejemplares similares
-
Preliminary molecular characterization of a proinflammatory and nociceptive molecule from the Echinometra lucunter spines extracts
por: Sciani, Juliana Mozer, et al.
Publicado: (2017) -
Application of Computational Methods for the Design of BACE-1 Inhibitors: Validation of in Silico Modelling
por: Bajda, Marek, et al.
Publicado: (2014) -
In Silico Design of BACE1 Inhibitor for Alzheimer's Disease by Traditional Chinese Medicine
por: Huang, Hung-Jin, et al.
Publicado: (2014) -
The modular nature of bradykinin-potentiating peptides isolated from snake venoms
por: Sciani, Juliana Mozer, et al.
Publicado: (2017) -
Potent bace-1 inhibitor design using pharmacophore modeling, in silico screening and molecular docking studies
por: John, Shalini, et al.
Publicado: (2011)